Hualan biological Herceptin monoclonal antibody clinical application accepted

。
Trastuzumab was originally developed by Roche, and its trade name is Herceptin It is used to treat breast cancer and metastatic breast cancer The price of a 440mg preparation is as high as 23000 yuan In 2013, the global sales of Herceptin reached US $6.839 billion, which is a heavyweight variety in the field of monoclonal antibody As its patent will expire next year, many domestic pharmaceutical enterprises, such as Guoyao Tongyi (000028 SZ) and Zhongxin Guojian, have joined the imitation army Hualan biological's monoclonal antibody business is considered to be one of the focuses of this year In addition to Herceptin, Hualan gene, a subsidiary of the company, also has three monoclonal antibody varieties, xiumeile, meiluohua and Avastin, under research Just last month, Xie Junmin, the company's chief financial officer and Secretary of the board, said in a conference call that the company would complete the clinical application of all four McAbs within this year At present, Hualan biology is mainly engaged in blood products and vaccines At present, the broad consensus of securities companies is that the company's vaccine business performance is average Although the above-mentioned monoclonal antibody products still need a long time to be listed to contribute income and profits, as a leading domestic biological product enterprise, Hualan biological's active layout of monoclonal antibody will help to improve its long-term growth space and gradually reduce the impact of cyclical and policy fluctuations in blood products on the company's profitability.